Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary Delivery
To assess the difference in the fate of the antibiotic colistin (COLI) after its pulmonary delivery as a powder or a solution, we developed a COLI powder and evaluated the COLI pharmacokinetic properties in rats after pulmonary administration of the powder or the solution. The amorphous COLI powder...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-06-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/12/6/557 |
id |
doaj-1117420f113041e1856723077907d212 |
---|---|
record_format |
Article |
spelling |
doaj-1117420f113041e1856723077907d2122020-11-25T03:20:57ZengMDPI AGPharmaceutics1999-49232020-06-011255755710.3390/pharmaceutics12060557Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary DeliveryFrédéric Tewes0Julien Brillault1Nicolas Gregoire2Jean-Christophe Olivier3Isabelle Lamarche4Christophe Adier5Anne-Marie Healy6Sandrine Marchand7INSERM U1070 “Pharmacology of anti-infective agents”, 1 rue Georges Bonnet, Pôle Biologie Santé, 86022 Poitiers Cedex, FranceINSERM U1070 “Pharmacology of anti-infective agents”, 1 rue Georges Bonnet, Pôle Biologie Santé, 86022 Poitiers Cedex, FranceINSERM U1070 “Pharmacology of anti-infective agents”, 1 rue Georges Bonnet, Pôle Biologie Santé, 86022 Poitiers Cedex, FranceUFR Médecine-Pharmacie Université de Poitiers, 6 rue de la milétrie, TSA 51115, 86073 Poitiers Cedex 9, FranceINSERM U1070 “Pharmacology of anti-infective agents”, 1 rue Georges Bonnet, Pôle Biologie Santé, 86022 Poitiers Cedex, FranceINSERM U1070 “Pharmacology of anti-infective agents”, 1 rue Georges Bonnet, Pôle Biologie Santé, 86022 Poitiers Cedex, FranceSSPC, The Science Foundation Ireland Research Centre for Pharmaceuticals, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Panoz Institute, D02 PN40 Dublin 2, IrelandINSERM U1070 “Pharmacology of anti-infective agents”, 1 rue Georges Bonnet, Pôle Biologie Santé, 86022 Poitiers Cedex, FranceTo assess the difference in the fate of the antibiotic colistin (COLI) after its pulmonary delivery as a powder or a solution, we developed a COLI powder and evaluated the COLI pharmacokinetic properties in rats after pulmonary administration of the powder or the solution. The amorphous COLI powder prepared by spray drying was characterized by a mass median aerodynamic diameter and fine particle fraction of 2.68 ± 0.07 µm and 59.5 ± 5.4%, respectively, when emitted from a Handihaler<sup>®</sup>. After intratracheal administration, the average pulmonary epithelial lining fluid (ELF): plasma area under the concentration versus time curves (AUC) ratios were 570 and 95 for the COLI solution and powder, respectively. However, the same COLI plasma concentration profiles were obtained with the two formulations. According to our pharmacokinetic model, this difference in ELF COLI concentration could be due to faster systemic absorption of COLI after the powder inhalation than for the solution. In addition, the COLI apparent permeability (P<sub>app</sub>) across a Calu-3 epithelium model increased 10-fold when its concentration changed from 100 to 4000 mg/L. Based on this last result, we propose that the difference observed in vivo between the COLI solution and powder could be due to a high local ELF COLI concentration being obtained at the site where the dry particles impact the lung. This high local COLI concentration can lead to a local increase in COLI P<sub>app</sub>, which is associated with a high concentration gradient and could produce a high local transfer of COLI across the epithelium and a consequent increase in the overall absorption rate of COLI.https://www.mdpi.com/1999-4923/12/6/557colistin dry powder inhalationpulmonary infectionsnebulizationpharmacokinetics modelingCalu-3 permeability |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Frédéric Tewes Julien Brillault Nicolas Gregoire Jean-Christophe Olivier Isabelle Lamarche Christophe Adier Anne-Marie Healy Sandrine Marchand |
spellingShingle |
Frédéric Tewes Julien Brillault Nicolas Gregoire Jean-Christophe Olivier Isabelle Lamarche Christophe Adier Anne-Marie Healy Sandrine Marchand Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary Delivery Pharmaceutics colistin dry powder inhalation pulmonary infections nebulization pharmacokinetics modeling Calu-3 permeability |
author_facet |
Frédéric Tewes Julien Brillault Nicolas Gregoire Jean-Christophe Olivier Isabelle Lamarche Christophe Adier Anne-Marie Healy Sandrine Marchand |
author_sort |
Frédéric Tewes |
title |
Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary Delivery |
title_short |
Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary Delivery |
title_full |
Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary Delivery |
title_fullStr |
Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary Delivery |
title_full_unstemmed |
Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary Delivery |
title_sort |
comparison between colistin sulfate dry powder and solution for pulmonary delivery |
publisher |
MDPI AG |
series |
Pharmaceutics |
issn |
1999-4923 |
publishDate |
2020-06-01 |
description |
To assess the difference in the fate of the antibiotic colistin (COLI) after its pulmonary delivery as a powder or a solution, we developed a COLI powder and evaluated the COLI pharmacokinetic properties in rats after pulmonary administration of the powder or the solution. The amorphous COLI powder prepared by spray drying was characterized by a mass median aerodynamic diameter and fine particle fraction of 2.68 ± 0.07 µm and 59.5 ± 5.4%, respectively, when emitted from a Handihaler<sup>®</sup>. After intratracheal administration, the average pulmonary epithelial lining fluid (ELF): plasma area under the concentration versus time curves (AUC) ratios were 570 and 95 for the COLI solution and powder, respectively. However, the same COLI plasma concentration profiles were obtained with the two formulations. According to our pharmacokinetic model, this difference in ELF COLI concentration could be due to faster systemic absorption of COLI after the powder inhalation than for the solution. In addition, the COLI apparent permeability (P<sub>app</sub>) across a Calu-3 epithelium model increased 10-fold when its concentration changed from 100 to 4000 mg/L. Based on this last result, we propose that the difference observed in vivo between the COLI solution and powder could be due to a high local ELF COLI concentration being obtained at the site where the dry particles impact the lung. This high local COLI concentration can lead to a local increase in COLI P<sub>app</sub>, which is associated with a high concentration gradient and could produce a high local transfer of COLI across the epithelium and a consequent increase in the overall absorption rate of COLI. |
topic |
colistin dry powder inhalation pulmonary infections nebulization pharmacokinetics modeling Calu-3 permeability |
url |
https://www.mdpi.com/1999-4923/12/6/557 |
work_keys_str_mv |
AT frederictewes comparisonbetweencolistinsulfatedrypowderandsolutionforpulmonarydelivery AT julienbrillault comparisonbetweencolistinsulfatedrypowderandsolutionforpulmonarydelivery AT nicolasgregoire comparisonbetweencolistinsulfatedrypowderandsolutionforpulmonarydelivery AT jeanchristopheolivier comparisonbetweencolistinsulfatedrypowderandsolutionforpulmonarydelivery AT isabellelamarche comparisonbetweencolistinsulfatedrypowderandsolutionforpulmonarydelivery AT christopheadier comparisonbetweencolistinsulfatedrypowderandsolutionforpulmonarydelivery AT annemariehealy comparisonbetweencolistinsulfatedrypowderandsolutionforpulmonarydelivery AT sandrinemarchand comparisonbetweencolistinsulfatedrypowderandsolutionforpulmonarydelivery |
_version_ |
1724615579112833024 |